Purchase this article with an account.
Koji Honda, Asako Ogawa, Ryo Obata, Yasuo Yanagi; Long-term treatment outcome of anti-VEGF therapy for myopic choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4979.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To investigate the long-term treatment outcome of anti-VEGF therapy for myopic CNV (mCNV).
Methods: In this retrospective study, 26 eyes of 26 patients with mCNV who underwent intravitreal injection of 1.25 mg bevacizumab. All eyes underwent best corrected visual acuity (BCVA) measurement before the treatment, and 1,2 and 3 years after the injection. Twelve eyes completed observations up to 5 years. The main outcome measures were changes in BCVA from the baseline.
Results: Mean patients’ age was 61.4±13.1 years old. At baseline, mean BCVA was 0.63±0.43 logMAR unit . Change in the BCVA in the 1,2 and 3 years were -0.14±0.29, -0.15±0.39 and -0.08±0.35. At four and five years, change in BCVA was -0.05±0.36 and 0.03±0.48. Proportions of patients that lost more than three line were 15.4, 11.5, 23.1, 30 and 41%, at 1, 2, 3, 4 and 5 years, respectively. Study eyes received a mean of 1.35, 0.38, 0.15, 0.25 and 0 injections at year 1,2,3,4 and 5. Chorioretinal atrophy was predominant findings that results in poor visual outcome.
Conclusions: Even with anti-VEGF therapy, patients with mCNV remain at long-term risk of visual decline due to chorioretinal atrophy.
This PDF is available to Subscribers Only